Rezolute (RZLT) Accumulated Depreciation & Amortization (2014 - 2025)
Rezolute recorded quarterly Accumulated Depreciation & Amortization of $138000.0 in Q2 2025, up 28.97% quarter-over-quarter from $107000.0 in Q2 2024, and up 28.97% year-over-year from $107000.0 in Q2 2024.
Rezolute's Accumulated Depreciation & Amortization history runs 12 years deep, the most recent figure standing at $138000.0 for Q2 2025.
- In Q2 2025, Accumulated Depreciation & Amortization rose 28.97% year-over-year to $138000.0; the TTM figure through Jun 2025 stood at $138000.0 (up 28.97% YoY), while the FY2025 annual figure was $138000.0, up 28.97% from the prior year.
- Accumulated Depreciation & Amortization came in at $138000.0 for Q2 2025 at Rezolute, up from $107000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $138000.0 in Q2 2025 to a low of $27000.0 in Q2 2021.
- A 5-year average of $76600.0 and a median of $71000.0 in 2023 frame the typical range for Accumulated Depreciation & Amortization.
- Across the five-year window, Accumulated Depreciation & Amortization soared 92.86% in 2021 and rose 28.97% in 2025, its largest moves.
- Rezolute's Accumulated Depreciation & Amortization stood at $27000.0 in 2021, then soared by 48.15% to $40000.0 in 2022, then jumped by 77.5% to $71000.0 in 2023, then soared by 50.7% to $107000.0 in 2024, then rose by 28.97% to $138000.0 in 2025.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $138000.0, $107000.0, and $71000.0 for Q2 2025, Q2 2024, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 138,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Jun 30, 2024 | 107,000.00 |
| Jun 30, 2024 | 107,000.00 |
| Jun 30, 2023 | 71,000.00 |
| Jun 30, 2023 | 71,000.00 |
| Jun 30, 2022 | 40,000.00 |
| Jun 30, 2022 | 40,000.00 |
| Jun 30, 2021 | 27,000.00 |
| Jun 30, 2021 | 27,000.00 |
| Jun 30, 2020 | 14,000.00 |
| Jun 30, 2020 | 14,000.00 |
| Jun 30, 2019 | 3,000.00 |
| Jun 30, 2019 | 3,000.00 |
| Mar 31, 2019 | 44,811.00 |
| Mar 31, 2019 | 44,811.00 |
| Dec 31, 2018 | 12,664.00 |
| Dec 31, 2018 | 12,664.00 |
| Sep 30, 2018 | 443,843.00 |
| Sep 30, 2018 | 443,843.00 |
| Jun 30, 2018 | 518,000.00 |
| Jun 30, 2018 | 518,000.00 |
| Mar 31, 2018 | 266,781.00 |
| Mar 31, 2018 | 266,781.00 |
| Dec 31, 2017 | 266,781.00 |
| Dec 31, 2017 | 266,781.00 |
| Sep 30, 2017 | 2.25 Mn |
| Sep 30, 2017 | 2.25 Mn |
| Jun 30, 2017 | 1.99 Mn |
| Jun 30, 2017 | 1.99 Mn |
| Mar 31, 2017 | 1.71 Mn |
| Mar 31, 2017 | 1.71 Mn |
| Dec 31, 2016 | 1.43 Mn |
| Dec 31, 2016 | 1.43 Mn |
| Sep 30, 2016 | 1.15 Mn |
| Sep 30, 2016 | 1.15 Mn |
| Jun 30, 2016 | 879,250.00 |
| Jun 30, 2016 | 879,250.00 |
| Mar 31, 2016 | 612,229.00 |
| Mar 31, 2016 | 612,229.00 |
| Dec 31, 2015 | 355,825.00 |
| Dec 31, 2015 | 355,825.00 |
| Sep 30, 2015 | 205,601.00 |
| Sep 30, 2015 | 205,601.00 |
| Jun 30, 2015 | 136,629.00 |
| Jun 30, 2015 | 136,629.00 |
| Jun 30, 2014 | 7,759.00 |
| Jun 30, 2014 | 7,759.00 |